FDA Approves Opdivo to Treat Advanced Esophageal Squamous Cell Carcinoma

The Food and Drug Administration (FDA) approved Opdivo (nivolumab) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy, according to Bristol Meyers Squibb – the agent’s manufacturer.


Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *